Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Febrile Neutropenia 6Neoplasms 4Neutropenia 2Hematologic Neoplasms 2Fever 2Sepsis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Emergencies 1

Interventions

Vincristine 20Cytarabine 19Methotrexate 18Dexamethasone 17Cyclophosphamide 17Mercaptopurine 16Daunorubicin 12Asparaginase 12Doxorubicin 10Prednisolone 9Granulocyte Colony-Stimulating Factor 8Idarubicin 7Etoposide 7Thioguanine 6Teniposide 6Rituximab 6Prednisone 6Vindesine 5Ifosfamide 5Stem Cell Transplantation 4fludarabine 3Mitoxantrone 3Hydrocortisone 3pegaspargase 2Ketamine 2Inotuzumab Ozogamicin 2Imatinib Mesylate 2Cladribine 2Cholecalciferol 2pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Meropenem × Clear all
NCT05784844 2024-09-19

Antimicrobial Revision in Persistent Febrile Neutropenia

Wake Forest University Health Sciences

Phase 4 Withdrawn
Classical hematologyLymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡